While the French phase 3 PRODIGE-7 trial had everyone saying bye-PEC to hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal cancer peritoneal carcinomatosis (T4 disease) due to a lack of any survival benefit, the Spanish phase 3 trial is back to say: but doesn’t local control count for something? | Arjona-Sánchez, JAMA Surg 2023
